• Appointed by the President of the Greater New Haven Chamber of Commerce for a term of seven years beginning January 1, 2023

As CEO of Biohaven, Dr. Coric has overseen its dramatic growth from an entrepreneurial start-up into a modern, publicly traded company listed on the New York Stock Exchange. Under his stewardship, Biohaven has focused on discovering, developing and commercializing life-changing therapies that address unmet medical needs. He successfully led the company through its first FDA approval and the launch of Nurtec® ODT (rimegepant; CGRP receptor antagonist) for the acute treatment of migraine, followed by the approval of an expanded indication for Nurtec ODT for the preventive treatment of episodic migraine — becoming the first all-in-one migraine medication for the acute and preventive treatment of migraine. Capitalizing on the extraordinary patient and shareholder value that Biohaven has built with Nurtec ODT and its CGRP franchise, Dr. Coric spearheaded the acquisition of Biohaven by Pfizer in May 2022 for approximately $13 billion in total consideration. He has positioned Biohaven on its new course continuing its growth trajectory, harnessing its proven drug development expertise and broad therapeutic portfolio comprised of early- and late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders, with little or no treatment options. These include epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA).

Dr. Coric has more than 20 years of drug discovery and clinical development experience at Yale School of Medicine and Bristol-Myers Squibb prior to leading Biohaven. Within the pharmaceutical industry, he has expertise working across therapeutic areas including neuroscience, virology, oncology and immuno-oncology. Since July 2001, Dr. Coric has also continued to serve as an Associate Clinical Professor of Psychiatry at Yale School of Medicine. He previously served as the inpatient chief of the Yale Clinical Neuroscience Research Unit and the director of the Yale Obsessive-Compulsive Disorder Research Clinic. He earned his medical degree from Wake Forest University School of Medicine and was an honors scholar in neurobiology and physiology at the University of Connecticut, where he received his Bachelor of Science degree.